Literature DB >> 21034846

Cell-mediated immunity in human brucellosis.

Panagiotis Skendros1, Georgios Pappas, Panagiota Boura.   

Abstract

Brucella can parasitize within human antigen-presenting cells modifying phagocytosis, phagolysosome fusion, antigen presentation, cytokine secretion, and apoptosis. Subversion of innate immune mechanisms by Brucella leads to defective Th1 immune responses and T-cell anergy in chronic brucellosis patients. This review summarizes the cellular immune responses in brucellosis, based on data derived exclusively from human cells or cell lines.
© 2010 Institut Pasteur. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 21034846     DOI： 10.1016/j.micinf.2010.10.015

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  28 in total

1.  TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro.

Authors:  Jia-Yun Li; Yuan Liu; Xiao-Xue Gao; Xiang Gao; Hong Cai
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

2.  Serial kinetics of the antibody response against the complete Brucella melitensis ORFeome in focal vertebral brucellosis.

Authors:  Anthony P Cannella; Jennifer C Lin; Li Liang; Vidya Atluri; Eduardo Gotuzzo; Philip L Felgner; Renee M Tsolis; Joseph M Vinetz
Journal:  J Clin Microbiol       Date:  2012-01-04       Impact factor: 5.948

3.  Evaluation of Regulatory T Cells in Patients with Acute and Chronic Brucellosis.

Authors:  Ali Ganji; Ghasem Mosayebi; Ehsanollah Ghaznavi-Rad; Khadije Khosravi; Nader Zarinfar
Journal:  Rep Biochem Mol Biol       Date:  2017-04

4.  Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.

Authors:  Lis N Velásquez; M Ayelén Milillo; M Victoria Delpino; Aldana Trotta; M Florencia Mercogliano; Roberto G Pozner; Roxana Schillaci; Patricia V Elizalde; Guillermo H Giambartolomei; Paula Barrionuevo
Journal:  Immunol Cell Biol       Date:  2016-11-29       Impact factor: 5.126

5.  Cell delivery of therapeutic nanoparticles.

Authors:  JoEllyn McMillan; Elena Batrakova; Howard E Gendelman
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

6.  Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.

Authors:  J Xu; Y Qiu; M Cui; Y Ke; Q Zhen; X Yuan; Y Yu; X Du; J Yuan; H Song; Z Wang; G Gao; S Yu; Y Wang; L Huang; Z Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-15       Impact factor: 3.267

7.  Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.

Authors:  Georgia Vrioni; Adamantios Bourdakis; Georgios Pappas; Vassiliki Pitiriga; Maria Mavrouli; Spyros Pournaras; Athanassios Tsakris
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

8.  Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.

Authors:  Anthony P Cannella; Cecilia S Lindestam Arlehamn; John Sidney; Kailash P Patra; Katherine Torres; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Eduardo Gotuzzo; Robert H Gilman; Alessandro Sette; Joseph M Vinetz
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

9.  Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.

Authors:  Gabriel Gomez; Jianwu Pei; Waithaka Mwangi; L Garry Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

Review 10.  Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.

Authors:  Gabriel Gomez; Leslie G Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  Front Cell Infect Microbiol       Date:  2013-05-16       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.